Oculis Holding AG Ordinary shares (OCS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oculis Holding AG Ordinary shares (OCS) has a cash flow conversion efficiency ratio of -0.081x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.98 Million) by net assets ($196.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Oculis Holding AG Ordinary shares stock valuation for the company's overall valuation and market capitalisation.
Oculis Holding AG Ordinary shares - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Oculis Holding AG Ordinary shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oculis Holding AG Ordinary shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oculis Holding AG Ordinary shares ranked by their cash flow conversion efficiency. See Oculis Holding AG Ordinary shares (OCS) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Xinneng Photovoltaic Technology Co Ltd
SHG:603105
|
0.082x |
|
Suzhou Cheersson Precision Metal Fo
SHE:002976
|
0.005x |
|
Oeneo SA
PA:SBT
|
0.161x |
|
Chongqing Shunbo Aluminum Co Ltd
SHE:002996
|
-0.025x |
|
Jiangxi Yuean Advanced Materials Co Ltd
SHG:688786
|
0.056x |
|
Caisse Regionale de Credit Agricole Mutuel Brie Picardie
PA:CRBP2
|
0.133x |
|
Sparebanken Møre
OL:MORG
|
-0.358x |
|
GKHT Medical Technology Co. Ltd. A
SHE:301370
|
N/A |
Annual Cash Flow Conversion Efficiency for Oculis Holding AG Ordinary shares (2020–2025)
The table below shows the annual cash flow conversion efficiency of Oculis Holding AG Ordinary shares from 2020 to 2025. View Oculis Holding AG Ordinary shares stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $196.29 Million | $-62.22 Million | -0.317x | +51.03% |
| 2024-12-31 | $73.38 Million | $-47.50 Million | -0.647x | -12.67% |
| 2023-12-31 | $93.73 Million | $-53.84 Million | -0.574x | -324.51% |
| 2022-12-31 | $-97.99 Million | $-25.07 Million | 0.256x | +12.82% |
| 2021-12-31 | $-60.95 Million | $-13.82 Million | 0.227x | -17.69% |
| 2020-12-31 | $-43.65 Million | $-12.03 Million | 0.276x | -- |
About Oculis Holding AG Ordinary shares
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candida… Read more